Supplementary Figure S13 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
Figure S13. Treatment with brigatinib, INK128, or brigatinib+INK128 did not cause overt weight loss, compared with vehicle-treated mice.
Fields of Study & Subjects
Meningioma and schwannoma management
Neurofibromatosis and Schwannoma Cases
PI3K/AKT/mTOR signaling in cancer
Publication details
- Publication date
- 27 January 2026